Cleminorexton

Cleminorexton
Clinical data
Other names	ORX750; ORX-750
Routes of; administration	Oral
Drug class	Orexin receptor agonist; Orexin OX2 receptor agonist; Wakefulness-promoting agent
Identifiers
	IUPAC name 1-fluoro-N-[(16S,17S)-4,6,23-trifluoro-11-oxo-8-oxa-12-azatetracyclo[17.3.1.02,7.012,17]tricosa-1(22),2(7),3,5,19(23),20-hexaen-16-yl]cyclopropane-1-sulfonamide;
CAS Number	2980518-93-0;
PubChem CID	176507653;
ChemSpider	133326679;
UNII	AL84E4VK26;
Chemical and physical data
Formula	C24H24F4N2O4S
Molar mass	512.52 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@@H]([C@@H]2CC3=C(C(=CC=C3)C4=C(C(=CC(=C4)F)F)OCCC(=O)N2C1)F)NS(=O)(=O)C5(CC5)F;
	InChI InChI=1S/C24H24F4N2O4S/c25-15-12-17-16-4-1-3-14(22(16)27)11-20-19(29-35(32,33)24(28)7-8-24)5-2-9-30(20)21(31)6-10-34-23(17)18(26)13-15/h1,3-4,12-13,19-20,29H,2,5-11H2/t19-,20-/m0/s1; Key:XGXKCWFIUAZZRS-PMACEKPBSA-N;

Cleminorexton (INNTooltip International Nonproprietary Name; former developmental code name ORX750) is an orexin OX₂ receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia.^[2]^[3]^[4]^[5]^[1] It is taken orally.^[1] The drug was originated by Orexia, was subsequently developed by Centessa Pharmaceuticals, and is now being developed by Eli Lilly and Company.^[2]^[3]^[5] As of November 2025, it is in phase 2 clinical trials for narcolepsy and idiopathic hypersomnia.^[2]^[3]

References

1 2 3 Manalac T (31 March 2026). "Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda". BioSpace. Retrieved 6 April 2026.
1 2 3 "ORX 750". AdisInsight. Springer Nature Switzerland AG. 11 November 2025. Retrieved 6 April 2026.
1 2 3 "Delving into the Latest Updates on Cleminorexton with Synapse". Synapse. PatSnap. 3 April 2026. Retrieved 6 April 2026.
↑ Shahzadi M, Monderer R, Thorpy MJ (November 2025). "Understanding idiopathic hypersomnia: diagnosis, pathophysiology, and management". Current Opinion in Pulmonary Medicine. 31 (6): 597–604. doi:10.1097/MCP.0000000000001221. PMID 40990641.
1 2 Waldron J (31 March 2026). "Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play". Fierce Biotech. Retrieved 6 April 2026.

This drug article relating to the nervous system is a stub. You can help Wikipedia by adding missing information.

[Manalac2026-1] 1 2 3 Manalac T (31 March 2026). "Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda". BioSpace. Retrieved 6 April 2026.

[AdisInsight-2] 1 2 3 "ORX 750". AdisInsight. Springer Nature Switzerland AG. 11 November 2025. Retrieved 6 April 2026.

[Synapse-3] 1 2 3 "Delving into the Latest Updates on Cleminorexton with Synapse". Synapse. PatSnap. 3 April 2026. Retrieved 6 April 2026.

[ShahzadiMondererThorpy2025-4] Shahzadi M, Monderer R, Thorpy MJ (November 2025). "Understanding idiopathic hypersomnia: diagnosis, pathophysiology, and management". Current Opinion in Pulmonary Medicine. 31 (6): 597–604. doi:10.1097/MCP.0000000000001221. PMID 40990641.

[Waldron2026-5] 1 2 Waldron J (31 March 2026). "Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play". Fierce Biotech. Retrieved 6 April 2026.

[1]

v t e Wakefulness-promoting agents
Catecholaminergic agents	Dopamine reuptake inhibitors (DRIs): Adrafinil^‡ Armodafinil Esmodafinil Mesocarb^‡ Modafinil Phenylpiracetam (fonturacetam) Norepinephrine reuptake inhibitors (NRIs): Atomoxetine Desipramine Reboxetine Viloxazine Norepinephrine–dopamine reuptake inhibitors (NDRIs): Amineptine^‡ Bupropion Dexmethylphenidate Methylphenidate Nomifensine^‡ Serdexmethylphenidate Solriamfetol Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs): Mazindol Norepinephrine releasing agents (NRAs): Ephedrine Pseudoephedrine Selegiline (via metabolites) Norepinephrine–dopamine releasing agents (NDRAs): Amphetamine Dextroamphetamine Levoamphetamine^‡ Lisdexamfetamine Methamphetamine Mixed amphetamine salts Pemoline^‡
Orexin receptor agonists	Alixorexton^§ Balumorexton^§ Cleminorexton^§ Danavorexton^§ Firazorexton^§ Ledasorexton^§ Oveporexton^†
Histamine H₃ receptor antagonists	Pitolisant Samelisant^§
Adenosine receptor antagonists	Caffeine Istradefylline Paraxanthine
Others	GABA_A receptor antagonists and negative allosteric modulators (e.g., clarithromycin, flumazenil, pentylenetetrazol (pentetrazol)) GABA_B receptor agonists (e.g., sodium oxybate/γ-hydroxybutyrate (GHB)) (via improved nightly sleep) Nicotinic acetylcholine receptor agonists (e.g., nicotine)
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III
See also: Stimulants List of investigational narcolepsy and hypersomnia drugs

See also

References